Eosinophil Peroxidase: A Biomarker for Eosinophilic Chronic Rhinosinusitis Agnostic of Polyp Status.

IL-5 biomarker chronic rhinosinusitis eosinophil peroxidase eosinophilia interleukin 5 nasal polyps sinusitis

Journal

The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378

Informations de publication

Date de publication:
31 May 2023
Historique:
revised: 03 05 2023
received: 22 12 2022
accepted: 15 05 2023
pmc-release: 30 11 2024
medline: 31 5 2023
pubmed: 31 5 2023
entrez: 31 5 2023
Statut: aheadofprint

Résumé

To evaluate eosinophil peroxidase (EPX) as a biomarker for tissue levels of eosinophilia, cytokines, and chemokines within chronic rhinosinusitis (CRS). Twenty-eight subjects undergoing sinonasal surgery were prospectively enrolled. Ethmoid tissue was analyzed with an in-house EPX immunoassay and a 48-plex cytokine-chemokine array. Clinical severity was assessed using SNOT-22 and Lund-Mackay scores. Subjects were grouped as follows: controls, polyp status (CRS with [CRSwNP] and without nasal polyps [CRSsNP]), tissue eosinophilia (eosinophilic CRS [eCRS], non-eosinophilic CRS [neCRS]), or combinations thereof (eCRSwNP, eCRSsNP, neCRSsNP). eCRS was defined as >10 eosinophils per high power field (HPF). Subjects without CRS or asthma were enrolled as controls. EPX was elevated in CRSwNP compared to control (p = 0.007), in eCRS compared to neCRS (p = 0.002), and in eCRSwNP along with eCRSsNP compared to neCRSsNP (p = 0.023, p = 0.015, respectively). eCRS displayed elevated IL-5 compared to neCRS (p = 0.005). No significant differences in EPX or IL-5 were observed between eCRSwNP and eCRSsNP. IL-5 was elevated in eCRSwNP (p = 0.019) compared neCRSsNP. Area under the receiver operator characteristic curve was 0.938 (95% CI, 0.835-1.00) for EPX and tissue eosinophilia, with an optimal cut-point of 470 ng/mL being 100% specific and 81.25% sensitive for tissue eosinophilia. Linear regression revealed a strong correlation between EPX and IL-5 (R EPX is associated with tissue eosinophilia in CRS patients regardless of polyp status. EPX correlates with IL-5 and could be potentially considered a biomarker for anti-IL-5 therapies. 3 Laryngoscope, 2023.

Identifiants

pubmed: 37255054
doi: 10.1002/lary.30787
pmc: PMC10687314
mid: NIHMS1903153
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R37 AI071106
Pays : United States

Informations de copyright

© 2023 The American Laryngological, Rhinological and Otological Society, Inc.

Références

Allergy. 2016 Apr;71(4):567-70
pubmed: 26645423
J Exp Med. 2019 May 6;216(5):1170-1181
pubmed: 30910796
Int Immunol. 2019 Feb 6;31(1):33-40
pubmed: 30239772
J Allergy Clin Immunol Pract. 2019 Nov - Dec;7(8):2812-2820.e3
pubmed: 31128376
Allergy Asthma Immunol Res. 2021 Jan;13(1):8-22
pubmed: 33191674
Int Forum Allergy Rhinol. 2021 Aug;11(8):1207-1219
pubmed: 33611865
Am J Rhinol Allergy. 2018 Jul;32(4):252-257
pubmed: 29862828
Rhinology. 2021 Aug 1;59(4):330-339
pubmed: 34350429
Int Forum Allergy Rhinol. 2017 Oct;7(10):957-962
pubmed: 28742240
Int Forum Allergy Rhinol. 2018 May;8(5):592-604
pubmed: 29337425
J Allergy Clin Immunol. 2005 Aug;116(2):362-9
pubmed: 16083791
Int Forum Allergy Rhinol. 2018 Dec;8(12):1421-1429
pubmed: 30091850
J Biol Chem. 1998 Jan 16;273(3):1764-8
pubmed: 9430724
Int Forum Allergy Rhinol. 2019 Apr;9(4):402-408
pubmed: 30570840
Clin Immunol. 2007 Dec;125(3):291-8
pubmed: 17911044
Int Forum Allergy Rhinol. 2021 Mar;11(3):213-739
pubmed: 33236525
Rhinology. 2020 Feb 20;58(Suppl S29):1-464
pubmed: 32077450
J Allergy Clin Immunol. 2016 May;137(5):1449-1456.e4
pubmed: 26949058
J Leukoc Biol. 1998 Jun;63(6):715-22
pubmed: 9620664
Am J Clin Pathol. 1981 May;75(5):693-700
pubmed: 7234755
Ann Allergy Asthma Immunol. 2022 Aug;129(2):160-168
pubmed: 35398492
J Leukoc Biol. 2003 Mar;73(3):356-62
pubmed: 12629149
J Leukoc Biol. 2000 Sep;68(3):400-4
pubmed: 10985257
Clin Exp Immunol. 2002 Feb;127(2):270-3
pubmed: 11876749
PLoS One. 2010 Jul 06;5(7):e11450
pubmed: 20625511
J Allergy Clin Immunol Pract. 2022 Jun;10(6):1454-1461
pubmed: 35231626
Thorax. 2002 May;57(5):449-51
pubmed: 11978925
Allergy. 2021 Nov;76(11):3349-3358
pubmed: 33948955
Curr Opin Allergy Clin Immunol. 2020 Feb;20(1):23-29
pubmed: 31688152
J Immunol Methods. 2012 Oct 31;384(1-2):10-20
pubmed: 22750539
Sci Rep. 2016 May 24;6:26604
pubmed: 27216292
J Clin Invest. 2018 Mar 1;128(3):997-1009
pubmed: 29400693
Int Forum Allergy Rhinol. 2021 Jan;11(1):8-15
pubmed: 32472743
Front Immunol. 2022 Jul 07;13:938691
pubmed: 35874692
J Allergy Clin Immunol. 2019 Jun;143(6):2284-2287.e6
pubmed: 30738839
J Allergy Clin Immunol. 2021 Apr;147(4):1306-1317
pubmed: 33326802
Otolaryngol Head Neck Surg. 2010 Jan;142(1):64-71
pubmed: 20096225
J Allergy Clin Immunol. 2022 Jul;150(1):22-32
pubmed: 35469844
J Allergy Clin Immunol. 2015 Mar;135(3):676-81.e1
pubmed: 25282015
Curr Allergy Asthma Rep. 2020 Apr 22;20(6):16
pubmed: 32323067
J Otolaryngol Head Neck Surg. 2019 May 29;48(1):23
pubmed: 31142355
Int Forum Allergy Rhinol. 2018 Jul;8(7):797-805
pubmed: 29437297
Allergy. 2018 Jul;73(7):1459-1469
pubmed: 29331025
J Allergy Clin Immunol. 2017 Dec;140(6):1705-1708.e3
pubmed: 28870464
Otolaryngol Head Neck Surg. 2015 Apr;152(2 Suppl):S1-S39
pubmed: 25832968
Am J Respir Cell Mol Biol. 1999 Sep;21(3):291-5
pubmed: 10460744
J Immunol. 2006 Nov 15;177(10):7340-5
pubmed: 17082653
Crit Rev Immunol. 2002;22(2):105-14
pubmed: 12433129
Int Forum Allergy Rhinol. 2012 Sep-Oct;2(5):376-85
pubmed: 22419386
Int Forum Allergy Rhinol. 2017 Apr;7(4):373-379
pubmed: 28042687

Auteurs

Beau M Idler (BM)

Mayo Clinic Alix School of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA.

Koji Iijima (K)

Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.

Sergei I Ochkur (SI)

Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.

Elizabeth A Jacobsen (EA)

Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.

Matthew A Rank (MA)

Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
Department of Otorhinolaryngology-Head and Neck Surgery, Mayo Clinic Arizona, Phoenix, Arizona, USA.

Hirohito Kita (H)

Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
Department of Otorhinolaryngology-Head and Neck Surgery, Mayo Clinic Arizona, Phoenix, Arizona, USA.

Devyani Lal (D)

Department of Otorhinolaryngology-Head and Neck Surgery, Mayo Clinic Arizona, Phoenix, Arizona, USA.

Classifications MeSH